174 related articles for article (PubMed ID: 37230161)
61. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
Jiang XL; Shen HW; Yu AM
Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
[TBL] [Abstract][Full Text] [Related]
62. Noncompetitive inhibition of indolethylamine-N-methyltransferase by N,N-dimethyltryptamine and N,N-dimethylaminopropyltryptamine.
Chu UB; Vorperian SK; Satyshur K; Eickstaedt K; Cozzi NV; Mavlyutov T; Hajipour AR; Ruoho AE
Biochemistry; 2014 May; 53(18):2956-65. PubMed ID: 24730580
[TBL] [Abstract][Full Text] [Related]
63. Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine - Implications for dose considerations.
Eckernäs E; Timmermann C; Carhart-Harris R; Röshammar D; Ashton M
Clin Transl Sci; 2022 Dec; 15(12):2928-2937. PubMed ID: 36088656
[TBL] [Abstract][Full Text] [Related]
64. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
65. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
Carbonaro TM; Eshleman AJ; Forster MJ; Cheng K; Rice KC; Gatch MB
Psychopharmacology (Berl); 2015 Jan; 232(1):275-84. PubMed ID: 24985890
[TBL] [Abstract][Full Text] [Related]
66. Trends in DMT and other tryptamine use among young adults in the United States.
Palamar JJ; Le A
Am J Addict; 2018 Oct; 27(7):578-585. PubMed ID: 30260086
[TBL] [Abstract][Full Text] [Related]
67. Chronic, Intermittent Microdoses of the Psychedelic
Cameron LP; Benson CJ; DeFelice BC; Fiehn O; Olson DE
ACS Chem Neurosci; 2019 Jul; 10(7):3261-3270. PubMed ID: 30829033
[TBL] [Abstract][Full Text] [Related]
68. Spectroscopic behavior of bufotenine and bufotenine N-oxide: Solvent and pH effects and interaction with biomembrane models.
Almeida E Silva G; Galvão Wakui V; Kato L; Marquezin CA
Biochim Biophys Acta Biomembr; 2024 Apr; 1866(4):184304. PubMed ID: 38408695
[TBL] [Abstract][Full Text] [Related]
69. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT
Riga MS; Lladó-Pelfort L; Artigas F; Celada P
Neuropharmacology; 2018 Nov; 142():219-230. PubMed ID: 29221792
[TBL] [Abstract][Full Text] [Related]
70. Optimization of separation and online sample concentration of N,N-dimethyltryptamine and related compounds using MEKC.
Wang MJ; Tsai CH; Hsu WY; Liu JT; Lin CH
J Sep Sci; 2009 Feb; 32(3):441-5. PubMed ID: 19137528
[TBL] [Abstract][Full Text] [Related]
71. Neuropharmacology of N,N-dimethyltryptamine.
Carbonaro TM; Gatch MB
Brain Res Bull; 2016 Sep; 126(Pt 1):74-88. PubMed ID: 27126737
[TBL] [Abstract][Full Text] [Related]
72. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
Frecska E; Szabo A; Winkelman MJ; Luna LE; McKenna DJ
J Neural Transm (Vienna); 2013 Sep; 120(9):1295-303. PubMed ID: 23619992
[TBL] [Abstract][Full Text] [Related]
73. 11C-labeling of indolealkylamine alkaloids and the comparative study of their tissue distributions.
Takahashi T; Takahashi K; Ido T; Yanai K; Iwata R; Ishiwata K; Nozoe S
Int J Appl Radiat Isot; 1985 Dec; 36(12):965-9. PubMed ID: 3866749
[TBL] [Abstract][Full Text] [Related]
74. Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).
Witowski CG; Hess MR; Jones NT; Pellitteri Hahn MC; Razidlo J; Bhavsar R; Beer C; Gonzalez-Velazquez N; Scarlett CO; Wenthur CJ; von Salm JL
Eur J Pharm Sci; 2024 Aug; 199():106803. PubMed ID: 38788435
[TBL] [Abstract][Full Text] [Related]
75. N,N-Dimethyltryptamine Production in Phalaris aquatica Seedlings: A Mathematical Model for its Synthesis.
Mack JP; Mulvena DP; Slaytor M
Plant Physiol; 1988 Oct; 88(2):315-20. PubMed ID: 16666301
[TBL] [Abstract][Full Text] [Related]
76. Comparing the Detection of Endogenous Psychedelics in Individuals With and Without Alleged Mediumistic Experiences.
Vinhosa Bastos MA; Haidamus de Oliveira Bastos PR; Dos Santos ML; Iandoli D; Boschi Portella R; Lucchetti G
Explore (NY); 2018 Nov; 14(6):448-452. PubMed ID: 30241696
[TBL] [Abstract][Full Text] [Related]
77. Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate.
Jiménez JH; Bouso JC
J Psychopharmacol; 2022 Aug; 36(8):905-919. PubMed ID: 35695604
[TBL] [Abstract][Full Text] [Related]
78. Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence.
Bassi M; Bilel S; Tirri M; Corli G; Di Rosa F; Gregori A; Alkilany AM; Rachid O; Roda E; Zauli G; Locatelli CA; Marti M
Psychopharmacology (Berl); 2024 Mar; 241(3):489-511. PubMed ID: 38214743
[TBL] [Abstract][Full Text] [Related]
79. Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
Rodrigues AV; Almeida FJ; Vieira-Coelho MA
J Psychoactive Drugs; 2019; 51(4):299-310. PubMed ID: 31018803
[TBL] [Abstract][Full Text] [Related]
80. In vivo long-term kinetics of radiolabeled n,n-dimethyltryptamine and tryptamine.
Vitale AA; Pomilio AB; Cañellas CO; Vitale MG; Putz EM; Ciprian-Ollivier J
J Nucl Med; 2011 Jun; 52(6):970-7. PubMed ID: 21622895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
